Fortress Biotech, Inc. (FBIO)

Fortress Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	85.11	84.51	75.74	68.79	45.6	36.63
Revenue Growth (YoY)	32.48%	11.58%	10.11%	50.86%	24.49%	36.26%
Cost of Revenue	27.03	26.66	30.78	32.08	14.59	10.53
Gross Profit	58.09	57.85	44.97	36.71	31.01	26.1
Selling, General & Admin	86.73	94.12	113.66	86.84	61.17	55.59
Research & Development	91.41	106.07	134.88	128.87	64.11	81.33
Other Operating Expenses	0	0	0	9.54	0	0
Operating Expenses	178.13	200.2	248.53	225.25	125.28	136.92
Operating Income	-120.04	-142.34	-203.56	-188.54	-94.27	-110.82
Interest Expense / Income	13.62	15.32	13.64	15.31	15.33	11.85
Other Expense / Income	-79.67	-97.54	-131.08	-139.62	-63.21	-82.71
Pretax Income	-54	-60.12	-86.13	-64.23	-46.39	-39.96
Income Tax	0.52	0.52	0.45	0.47	0.14	0
Net Income	-54.52	-60.64	-86.58	-64.7	-46.53	-39.96
Preferred Dividends	8.34	8.03	8.03	0	0	0
Net Income Common	-62.86	-68.67	-94.61	-64.7	-46.53	-39.96
Shares Outstanding (Basic)	17	8	6	5	5	4
Shares Outstanding (Diluted)	17	8	6	5	5	4
Shares Change	152.52%	36.89%	8.78%	13.46%	31.61%	25.88%
EPS (Basic)	-6.10	-8.47	-15.97	-11.85	-21.45	-27.90
EPS (Diluted)	-6.10	-8.47	-15.97	-11.85	-21.45	-27.90
Free Cash Flow	-104.46	-122.29	-181.99	-121.51	-86.81	-99.71
Free Cash Flow Per Share	-6.09	-15.08	-30.72	-22.31	-18.08	-27.34
Gross Margin	68.25%	68.45%	59.37%	53.36%	67.99%	71.25%
Operating Margin	-141.04%	-168.43%	-268.76%	-274.08%	-206.74%	-302.54%
Profit Margin	-73.85%	-81.25%	-124.91%	-94.06%	-102.03%	-109.09%
Free Cash Flow Margin	-122.72%	-144.70%	-240.27%	-176.63%	-190.37%	-272.21%
EBITDA	-31.95	-36.73	-63.13	-44.61	-27.16	-24.63
EBITDA Margin	-37.54%	-43.46%	-83.35%	-64.84%	-59.56%	-67.24%
Depreciation & Amortization	8.43	8.08	9.35	4.32	3.91	3.48
EBIT	-40.38	-44.8	-72.48	-48.92	-31.06	-28.11
EBIT Margin	-47.44%	-53.01%	-95.70%	-71.12%	-68.12%	-76.75%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).